Authors

Expert Teams, Exceptional Outcomes: AHN Cancer Institute’s Disease Site Centers Drive Innovation

AHN Cancer Institute’s Centers of Excellence unite teams of experts to provide patients with high-quality, collaborative care in a supportive environment.

Choosing Your Path

Megan M. Dupuis, MD, shares the complex journey she traveled during medical training and how it brought her to the academic setting.

Targeting Transcription as a New Frontier in Advanced Pancreatic Cancer

A new focus of research has reconsidered the mechanisms in regulating transcription as a novel target for advanced pancreatic ductal adenocarcinoma.

Oncology Fellows Derive the Greatest Benefit From Advanced Research Training

Aimed at growing the translational workforce, most hubs offer different accelerated advanced degree opportunities to oncology trainees, such as master’s degrees in clinical and/or translational research, or graduate certificates.

Enfortumab Vedotin Shows Manageable Safety in Older Patients With Urothelial Carcinoma

Enfortumab vedotin demonstrated a manageable safety profile and no unexpected toxicities in patients aged 80 years and older with urothelial carcinoma.

Getting the Best From Mentorship

Mentors may help in career development, personal matters, research activities, and professional growth.

Frontline Therapeutic Planning for Metastatic Renal Cell Carcinoma

In this review, authors highlight multidisciplinary treatment for patients with advanced disease, and integrating systemic therapy options with surgery and radiation therapy.

In the Trenches With the Fellows

Mili Arora, MD, talks about changing the fellowship program at UC Davis, the effect the COVID-19 pandemic has had on her trainees, and the importance of working late nights with her fellows.

Zanubrutinib May Be Viable Option After Acalabrutinib Intolerance in B-Cell Malignancies

Patients with B-cell malignancies who were intolerant to treatment with acalabrutinib experienced clinically meaningful benefits when treated with zanubrutinib, suggesting zanubrutinib may be a viable treatment option for this population.

Stage Is Set for Continued Progress in the Melanoma Clinic

Unprecedented treatment advances have been made during the last decade for patients with advanced melanoma.

ASCP’s Outstanding Education Initiatives Receive Prestigious Awards

Two innovative ASCP education initiatives have received accolades from the Alliance for Continuing Education in the Health Professions.

Managing Unseen Risks: Understanding Recurrence in Early Breast Cancer With No or Limited Nodal Involvement

A Conversation about Somatic, Incidental Germline, and Standalone Germline Testing in Clinical Practice

Sponsored Content by Tempus

The Role of Genetics in Cancer Care Continues to Expand

Genetic screening and testing have only recently become an integral part of cancer care.

World Lung Cancer Expert Diagnosed with Advanced Lung Cancer

D. Ross Camidge, MD, PhD, has spent his career fighting lung cancer. In 2022, that fight turned personal when he received a diagnosis of his own.

The Power of No, the Value of Yes

Brian I. Rini, MD, and Matthew Tucker, MD, sit down to discuss developing a career path and building a résumé, the value of writing review articles early in fellowship, the power of saying no, and the importance of saying yes.

Fellows Can Join the Fight Against Cancer Misinformation Online

Many cancer organizations across the United States and internationally acknowledge a need for in-novative uses of social technology to improve cancer-related support and information provision.

Gemcitabine Intravesical System Yields Low Rate of Radical Cystectomy in BCG-Unresponsive, High-Risk NMIBC

Gemcitabine intravesical system in BCG-unresponsive, high-risk NMIBC led to high CR rates and low radical cystectomy rates.

Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma

Real-world data confirm the importance of tumor debulking with bridging therapy to reduce the risk of parkinsonism and NRM with cilta-cel in myeloma.

Trainees Deserve Better Feedback

Feedback plays a key role in medical edu-cation and faculty development as it allows everyone to evaluate their performance and improve their intrapersonal skills.

Novel Frontline Combinations Influence Later-Line Treatment Strategies in SCLC

While progress in outcomes has been greater in non–small cell lung cancer, recent advances, including molecularly targeted therapies against EGFR and ALK, checkpoint inhibitors that boost immune response, improved staging, and video-assisted surgery have all contributed to progress in treatment of all types of lung cancer, including in SCLC.

Dr Dholaria on the Mechanism of Action of P-BCMA-ALLO1 in Multiple Myeloma

Bhagirathbhai Dholaria, MBBS, discusses the mechanism of action of P-BCMA-ALLO1 in relapsed/refractory multiple myeloma.

Polatuzumab Vedotin Substitution in R-mini-CHOP Does Not Worsen High-Grade Toxicities in DLBCL

Using polatuzumab vedotin instead of vincristine in a reduced-dose regimen of rituximab, cyclophosphamide, doxorubicin, and prednisone was not found to increase grade 3/4 hematologic toxicities, infection risk, or neuropathy in elderly patients with untreated diffuse large B-cell lymphoma.

Advanced Systemic Mastocytosis: Expert Insight into Epidemiology, Diagnosis, and Treatment

Learn more about the epidemiology, diagnosis, and treatment of advanced systemic mastocytosis in this summary from an expert multidisciplinary case-based discussion.

Single-Center, Retrospective Data Show Low Rate of Lifileucel Infusion Following Referral in Advanced Melanoma

Only a proportion of patients with advanced melanoma proceeded to TIL therapy following referral in a real-world setting.

Mentoring Oncologists in the Era of Social Distancing

Mentoring is critically important to the development of young academic hematology/oncology trainees.

Biomarkers Drive ICIs in Colon Cancer

December 14, 2020 - Immunotherapy agents have shown efficacy in malignant melanoma, kidney cancer, and non–small cell lung cancer, and investigators are examining the efficacy of checkpoint inhibitors in less immunogenic tumors such as colon cancer, particularly in tumors with high microsatellite instability and deficient mismatch repair genes.